SKIN ELEMENTS LIMITED

==> picture [90 x 39] intentionally omitted <==

JUNE 2023

ANNUAL GENERAL MEETING PRESENTATION

ASX:SKN

and its controlled entities

SKIN ELEMENTS LIMITED ABN: 90 608 047 794

The Board of Directors

==> picture [201 x 134] intentionally omitted <==

Mr Peter Malone Executive Chairman and Chief Executive Officer / Managing Director

Peter Malone has over 30 years’ experience in global financial markets in key leadership roles. Mr Malone is an international entrepreneur and has been responsible for raising in excess of AUD$150 million for innovative technology development programmes.

Mr Malone is responsible for the strategic direction of the Company and is the Executive Chairman and Chief Executive Officer / Managing Director of the Company. He has a proven track record in developing and managing the commercialisation of disruptive new technology companies from idea stage through to reality.

==> picture [200 x 134] intentionally omitted <==

Mr Filippo (Phil) Giglia Independent Non-Executive Director

Phil Giglia is a Chartered Accountant with more than 30 years’ experience, with a strong depth of expertise in the small to medium enterprise sector. He is also a Registered Tax Agent and Company Auditor.

Mr Giglia worked for leading global accountancy firm Price Waterhouse Coopers from 1985 to 1991.

He is the founder and principal of Perth accountancy practice, Giglia & Associates, and is also a director of Global Marine Enclosures Pty Ltd.

==> picture [200 x 134] intentionally omitted <==

Mr Stuart Usher Independent Non-Executive Director and Company Secretary

Mr Usher is a Certified Practicing Accountant and Chartered Company Secretary with over 25 years experience in the management and corporate affairs of public listed companies in Australia and Internationally.

He has extensive experience across many industries focusing on corporate & financial management, strategy & planning, mergers & acquisitions, and investor relations & corporate governance.

Part One Resolutions

==> picture [55 x 16] intentionally omitted <==

	Lodged For Lodged Open Lodged Against Total Votes
Resolution 01 REMUNERATION REPORT	Votes 80,044,495 413,268 139,545 80,597,308
	99.31% 0.51% % 0.17%
	Holders 26 4 3
Resolution 02 APPROVAL OF 10% PLACEMENT FACILITY	Votes 170,193,893 413,268 139,545 170,746,706
	99.68% 0.24% % 0.08%
	Holders 38 4 3
Resolution 03 RE-ELECTION OF MR FILIPPO (PHIL) GIGLIA AS DIRECTOR	Votes 166,624,616 413,268 139,545 167,177,429
	99.67% 0.25% % 0.08%
	Holders 37 4 1
Resolution 04 ELECTION OF MR STUART DOUGLAS USHER AS A DIRECTOR	Votes 171,693,893 413,268 139,545 172,246,706
	99.68% 0.24% % 0.08%
	Holders 39 4 3

Part Two Resolutions

==> picture [55 x 16] intentionally omitted <==

	Lodged For Lodged Open Lodged Against Total Votes
Resolution 05 RATIFICATION OF PRIOR ISSUE OF OPTIONS - LISTING RULE 7.1	Votes 171,748,438 413,268 85,000 172,246,706
	99.71% 0.24% % 0.05%
	Holders 40 4 2
Resolution 06 RATIFICATION OF PRIOR ISSUE OF SHARES - LISTING RULE 7.1A	Votes 171,693,893 467,813 85,000 172,246,706
	99.68% 0.27% % 0.05%
	Holders 39 5 2
Resolution 07 PROPOSED ISSUE OF SHARES AND OPTIONS TO 708 CAPITAL PTY LTD FOR UNDERWRITING FEE	Votes 171,748,438 413,268 85,000 172,246,706
	99.71% 0.24% % 0.05%
	Holders 40 4 2
Resolution 08 PROPOSED ISSUE OF OPTIONS TO 708 CAPITAL PTY LTD FOR LEAD MANAGER SERVICES	Votes 171,748,438 413,268 85,000 172,246,706
	99.71% 0.24% % 0.05%
	Holders 40 4 2

Biotechnology to Deliver Healthy Lifestyle and Healthy Planet

The early 21st century has emphasised the importance of sustainable consumption driven by healthy lifestyle and healthy planet.

The global embrace of new technologies such as renewable energy, electric vehicles, and recyclable or reusable materials is clear evidence.

There is increasing evidence of the effects of harmful, aggressive toxic ingredients and in our bodies.

Skin Elements is at the forefront of this revolution with the development of its high performance proprietary skin bio-technology - a plant based SE Formula[TM] technology - replacing toxic chemicals in skincare.

This innovative research and development path has seen our $36m invested in the research and development of the core SE Formula technology and development of numerous applications.

As a key phase of the global development process Skin Elements worked with a global network of partners, distributors, laboratories and regulators to ensure the worlds healthiest products.

Commitment to Safety and Sustainability

Skin Elements was founded on the principle of improving health and wellness of people, across the globe, without harming our planet.

==> picture [322 x 222] intentionally omitted <==

The company is committed to creating a safe and supportive environment for everyone. We are dedicated to making a difference in the lives of our customers and a positive impact on our planet.
The SE Formula[TM] technology is developed on Naturopathic principles using organic and natural ingredients.

Skin Elements supports:

==> picture [41 x 48] intentionally omitted <==

----- Start of picture text -----

Reef Friendly
----- End of picture text -----

==> picture [40 x 45] intentionally omitted <==

==> picture [35 x 34] intentionally omitted <==

==> picture [40 x 35] intentionally omitted <==

Biodegradable

Australian Made

What we Set Out to Do

The process of research and development of the SE FormulaTM biotechnology followed a broadly three phase process:

PHASE 1

Investigation into ingredients and processes to prepare prototype formulations to achieve specific criteria

PHASE 2

Produce test batches and undertake product trials, test marketing and regulatory certifications

PHASE 3

Scale up & Commercialisation

What we Developed

SE FORMULA

Phase 1, research and development of the SE Formula[TM] biotechnology creating a unique antimicrobial process that can be used in many different applications.

==> picture [227 x 56] intentionally omitted <==

----- Start of picture text -----

+
----- End of picture text -----

Sun Protection

Therapeutic Pawpaw

Hygiene Disinfectants

Soléo Organics was the first application borne out of the SE Formula[TM ] research & development that resulted in a major advancement in sun protection technology.

Soléo Organics is now commencing phase 3 with investigations into scale manufacturing of white label ranges for international health retailers.

The PapayaActivs natural therapeutics product range combines the power of Papaya with proven ingredients traditionally used in herbal medicine.

PapayaActivs is completing phase 2 with improvements in the formulations and expansion of the product range.

Hygiene Disinfectant ranges, formulated for use in households and in agriculture.

SuprCuvr and Eco Nurture are

commencing phase 2 following numerous initial trials in cleaning and agricultural applications. This has progressed into expanded trials in kiwifruit orchards and contract hygiene cleaning services.

Disclaimer

All information, terms and pricing set out in this document is indicative, based on, among other things, market conditions at the time of this writing and is subject to change without notice. This document has been prepared by Skin Elements Limited (SKN).

The information contained in this document is not investment or financial product advice and is not intended to be used as the basis for making an investment decision. Please note that, in providing this document, Skin Elements Limited (SKN) has not considered the objectives, financial position or needs of any particular recipient. SKN strongly suggests that investors consult a financial advisor prior to making an investment decision.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this document. To the maximum extent permitted by law, none of Skin Elements Limited, its related bodies corporate, shareholders or respective directors, officers, employees, agents or advisors, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence for any loss arising from the use of information contained in this document.

This document includes “forward looking statements” within the meaning of securities laws of applicable jurisdictions. Forward looking statements can generally be identified by the use of the words “anticipate”, “believe”, “expect”, “project”, “forecast”, “estimate”, “likely”, “intend”, “should”, “could”, “may”, “target”, “plan” “guidance” and other similar expressions. Indications of, and guidance on, future earning or dividends and financial position and performance are also forward-looking statements. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of Skin Elements Limited and its officers, employees, agents or associates, that may cause actual results to differ materially from those expressed or implied in such statement. Actual results, performance or achievements may vary materially from any projections and forward looking statements and the assumptions on which those statements are based. Readers are cautioned not to place undue reliance on forward looking statements and Skin Elements Limited assumes no obligation to update such information.

This document is not, and does not constitute, an offer to sell or the solicitation, invitation or recommendation to purchase any securities or financial instrument and neither this presentation nor anything contained in it forms the basis of any contract or commitment. Any offer or sale of securities or financial instrument will be made pursuant to definitive documentation, which describes the terms of the offer (Offer Document). An Offer Document for any offer of securities or convertible note will be made available when the securities or convertible note are offered. Prospective investors should consider the Offer Document in deciding whether to acquire securities or convertible note under the offer. Prospective investors who want to acquire securities or convertible note under the offer will need to complete a convertible note deed and/or an application form that is in or accompanies the Offer Document.

==> picture [161 x 52] intentionally omitted <==